{"uri":"/api/stitches/v1/684897.json","count":3,"data":[{"Synonyms":["CEFOTETAN DISODIUM SALT [MI]","CEFOTETAN DISODIUM SALT","CEFOTETAN DISODIUM [VANDF]","CEFOTETAN DISODIUM [WHO-DD]","CEFOTETAN DISODIUM [MART.]","CEFOTETAN DISODIUM [ORANGE BOOK]","CEFOTETAN SODIUM [JAN]","CEFOTETAN DISODIUM [USP]","CEFOTETAN DISODIUM [USAN]","(6R,7S)-7-(4-(CARBAMOYLCARBOXYMETHYLENE)-1,3-DITHIETANE-2-CARBOXAMIDO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, DISODIUM SALT","(6R,7S)-4-((2-CARBOXY-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-7-YL)CARBAMOYL)-1,3-DITHIETANE-.DELTA.(SUP 2,.ALPHA.)-MALONAMIC ACID, DISODIUM SALT","5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((4-(2-AMINO-1-CARBOXY-2-OXOETHYLIDENE)-1,3-DITHIETAN-2-YL)CARBONYL)AMINO)-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-, DISODIUM SALT, (6R-(6.ALPHA.,7.ALPHA.))-","YM-09330","CEFOTAN","CEFOTETAN DISODIUM","CEFOTETAN SODIUM"],"EVMPD":["SUB01124MIG"],"ActiveMoieties":["48SPP0PA9Q"],"ECHA (EC/EINECS)":["277-834-9"],"SMILES":"[Na+].[Na+].[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C4S\\C(S4)=C(/C(N)=O)C([O-])=O)OC)C([O-])=O","MERCK INDEX":["M3205"],"CAS":["74356-00-6"],"References":["CEFOTETAN DISODIUM SALT [MI]","CEFOTETAN DISODIUM [VANDF]","CEFOTETAN DISODIUM [WHO-DD]","CEFOTETAN DISODIUM [MART.]","CEFOTETAN DISODIUM [ORANGE BOOK]","CEFOTETAN SODIUM [JAN]","CEFOTETAN DISODIUM [USP]","CEFOTETAN DISODIUM [USAN]","SRS import [0GXP746VXB]","SRS CODE IMPORT","MERCK","NDF-RT","WHO-DD","MARTINDALE 2011","ORANGE BOOK 2011","KEGG 2011","USP 33","USP DICTIONARY 2011","USP DICTIONARY 2010","USP Dictionary 2010","KEGG"],"MOLFILE":"0GXP746VXB\n  Marvin  11101716572D          \n\n 39 40  0  0  1  0            999 V2000\n    7.6087   -4.3135    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    7.6087   -5.1068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    7.0623   -5.6484    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    8.5208   -5.1068    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    8.5208   -4.3135    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    9.2951   -3.9382    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    9.9413   -4.2849    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    9.9413   -5.1068    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   10.6872   -5.5296    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   11.3998   -5.1590    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n   12.1124   -5.5771    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   13.0103   -5.2873    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n   13.6611   -6.0047    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n   13.0103   -6.7553    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n   12.1124   -6.4086    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n   13.1765   -4.4085    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    9.2429   -5.5106    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    9.2429   -6.3277    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    8.4970   -6.7649    0.0000 O   0  5  0  0  0  0  0  0  0  0  0  0\n    9.9128   -6.8456    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    8.5208   -3.5913    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0\n    6.7536   -4.3135    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    6.3260   -3.6674    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    5.6182   -3.6674    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    5.0528   -4.2374    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    4.3829   -3.7623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    4.9625   -3.1162    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    3.5183   -3.7623    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    3.0338   -3.0403    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    2.1074   -3.0403    0.0000 O   0  5  0  0  0  0  0  0  0  0  0  0\n    3.4471   -2.3277    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    3.1335   -4.4370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    3.6703   -5.1068    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    2.2594   -4.4370    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    6.6633   -3.0925    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    7.6087   -3.5628    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    8.2928   -2.7837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    4.2167   -6.8693    0.0000 Na  0  3  0  0  0  0  0  0  0  0  0  0\n    4.2167   -6.8693    0.0000 Na  0  3  0  0  0  0  0  0  0  0  0  0\n  3  2  2  0  0  0  0\n  2  4  1  0  0  0  0\n  4  5  1  0  0  0  0\n  5  1  1  0  0  0  0\n  6  5  1  0  0  0  0\n  7  6  1  0  0  0  0\n  8  7  1  0  0  0  0\n  9  8  1  0  0  0  0\n 10  9  1  0  0  0  0\n 11 10  1  0  0  0  0\n 12 11  1  0  0  0  0\n 13 12  1  0  0  0  0\n 14 13  2  0  0  0  0\n 14 15  1  0  0  0  0\n 15 11  2  0  0  0  0\n 16 12  1  0  0  0  0\n  8 17  2  0  0  0  0\n 17  4  1  0  0  0  0\n 18 17  1  0  0  0  0\n 19 18  1  0  0  0  0\n 20 18  2  0  0  0  0\n  5 21  1  6  0  0  0\n  1 22  1  1  0  0  0\n 23 22  1  0  0  0  0\n 24 23  1  0  0  0  0\n 25 24  1  0  0  0  0\n 26 25  1  0  0  0  0\n 26 27  1  0  0  0  0\n 27 24  1  0  0  0  0\n 28 26  2  0  0  0  0\n 29 28  1  0  0  0  0\n 30 29  1  0  0  0  0\n 31 29  2  0  0  0  0\n 32 28  1  0  0  0  0\n 33 32  2  0  0  0  0\n 34 32  1  0  0  0  0\n 35 23  2  0  0  0  0\n  1 36  1  6  0  0  0\n 37 36  1  0  0  0  0\n  2  1  1  0  0  0  0\nM  CHG  4  19  -1  30  -1  38   1  39   1\nM  STY  1   1 MUL\nM  SCN  1   1 HT \nM  SAL   1  2  38  39\nM  SPA   1  1  38\nM  SDI   1  4    3.7967   -7.2893    3.7967   -6.4493\nM  SDI   1  4    4.6367   -6.4493    4.6367   -7.2893\nM  SMT   1 2\nM  END\n","name":"0GXP746VXB","NCI_THESAURUS":["C47437"],"ChEMBL":["CHEMBL474579"],"PreferredName":["CEFOTETAN DISODIUM"],"id":"0GXP746VXB","RXCUI":["203141"],"UNII":["0GXP746VXB"]},{"EVMPD":["SUB07406MIG"],"ActiveMoieties":["48SPP0PA9Q"],"ECHA (EC/EINECS)":["274-093-3"],"WHO-ATC":["J01DC05"],"INN":["4931"],"MESH":["D015313"],"MERCK INDEX":["M3205"],"WIKIPEDIA":["CEFOTETAN"],"NCI_THESAURUS":["C61664"],"ChEMBL":["CHEMBL474579"],"PreferredName":["CEFOTETAN"],"id":"48SPP0PA9Q","UNII":["48SPP0PA9Q"],"WHO-VATC":["QJ01DC05"],"Synonyms":["CEFOTETAN [JAN]","CEFOTETAN [VANDF]","(6R,7S)-4-((2-CARBOXY-7-METHOXY-3-(((1-METHYL-1H-TETRAZOL-5-YL)THIO)METHYL)-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-7-YL)CARBAMOYL)-1,3-DITHIETANE-.DELTA.(SUP 2,.ALPHA.)-MALONAMIC ACID","CEFOTETAN [WHO-DD]","CEFOTETAN [USP-RS]","ICI-156834","ICI 156,834","CEFOTETAN [MI]","CEFOTETAN [MART.]","CEFOTETAN [USP]","CEFOTETAN [USAN]","CEFOTETAN [INN]","CEFOTETAN","ICI-156,834"],"NDF-RT":["N0000175488","N0000011161","N0000011161","N0000011161","N0000011161","N0000011161","N0000011161","N0000011161","N0000011161","N0000011161","N0000011161","N0000011161","N0000011161"],"SMILES":"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C4S\\C(S4)=C(/C(N)=O)C(O)=O)OC)C(O)=O","LactMed":["69712-56-7"],"CAS":["69712-56-7"],"DRUG BANK":["DB01330"],"References":["WEBSITE","WEBSITE","JAN","CEFOTETAN [VANDF]","CEFOTETAN [WHO-DD]","CEFOTETAN [USP-RS]","CEFOTETAN [MI]","CEFOTETAN [MART.]","CEFOTETAN [USP]","CEFOTETAN [USAN]","CEFOTETAN [INN]","USP Dictionary 2010","SRS import [48SPP0PA9Q]","SRS CODE IMPORT","NDF-RT","USP DICTIONARY 2012","WHO-DD","USP/NF","MERCK INDEX","MARTINDALE 2011","USP 33","USP DICTIONARY 2011","INN 2010","FDA_SRS","USP DICTIONARY 2010"],"MOLFILE":"48SPP0PA9Q\n  Marvin  11101716382D          \n\n 37 40  0  0  1  0            999 V2000\n    2.0412   -1.5655    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n    2.9661   -2.3389    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    2.0412   -2.3522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    2.9555   -1.5655    0.0000 C   0  0  2  0  0  0  0  0  0  0  0  0\n   -1.1801   -0.9994    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    6.5435   -2.8253    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    3.6731   -2.7588    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    1.1880   -1.5787    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n   -2.0439   -1.0126    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   -0.5103   -1.4857    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n   -0.6007   -0.3668    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    7.4365   -2.5355    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    6.5594   -3.6545    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    7.4365   -4.0027    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    0.0558   -0.9196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    8.0903   -3.2532    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n    3.7289   -1.1880    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    4.3747   -2.3522    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    0.7628   -0.9196    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   -2.4293   -1.6824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n   -2.5303   -0.2870    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    3.6731   -3.5748    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    5.8286   -2.4080    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0\n    4.3747   -1.5309    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    1.4990   -2.8944    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    5.1163   -2.7774    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    2.0332   -0.8133    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    1.0977   -0.3429    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n   -1.8924   -2.3522    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n   -2.1156    0.4199    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    4.3508   -4.0930    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n   -3.3064   -1.6930    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0\n   -3.4525   -0.2738    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    7.6066   -1.6585    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    2.9315   -4.0133    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0\n    2.7269   -0.0319    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0\n    2.9874   -0.8399    0.0000 H   0  0  0  0  0  0  0  0  0  0  0  0\n  2  4  1  0  0  0  0\n  3  1  1  0  0  0  0\n  4  1  1  0  0  0  0\n  5 11  1  0  0  0  0\n  6 23  1  0  0  0  0\n  7  2  1  0  0  0  0\n  1  8  1  1  0  0  0\n  9  5  2  0  0  0  0\n 10 15  1  0  0  0  0\n 11 15  1  0  0  0  0\n 12  6  1  0  0  0  0\n 13  6  2  0  0  0  0\n 14 13  1  0  0  0  0\n 15 19  1  0  0  0  0\n 16 12  1  0  0  0  0\n 17  4  1  0  0  0  0\n 18 24  1  0  0  0  0\n 19  8  1  0  0  0  0\n 20  9  1  0  0  0  0\n 21  9  1  0  0  0  0\n 22  7  1  0  0  0  0\n 23 26  1  0  0  0  0\n 24 17  1  0  0  0  0\n 25  3  2  0  0  0  0\n 26 18  1  0  0  0  0\n  1 27  1  6  0  0  0\n 28 19  2  0  0  0  0\n 29 20  2  0  0  0  0\n 30 21  2  0  0  0  0\n 31 22  2  0  0  0  0\n 32 20  1  0  0  0  0\n 33 21  1  0  0  0  0\n 34 12  1  0  0  0  0\n 35 22  1  0  0  0  0\n 36 27  1  0  0  0  0\n  4 37  1  6  0  0  0\n  2  3  1  0  0  0  0\n 10  5  1  0  0  0  0\n  7 18  2  0  0  0  0\n 16 14  2  0  0  0  0\nM  END\n","EPA CompTox":["69712-56-7"],"name":"48SPP0PA9Q","RXCUI":["2187"]},{"mechanism-of-action":"The bactericidal action of cefotetan results from inhibition of cell wall synthesis by binding and inhibiting the bacterial penicillin binding proteins which help in the cell wall biosynthesis.","synonyms":["(6R,7S)-7-(4-(Carbamoylcarboxymethylene)-1,3-dithiethane-2-carboxamido)-7-methoxy-3-(((1-methyl-1H-tetrazol-5- yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2- carboxylic acid","Cefotetanum"],"pharmacodynamics":"Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. ","description":"retina homeostasis","groups":["approved"],"SMILES":"[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)C1SC(S1)=C(C(N)=O)C(O)=O)OC)C(O)=O","half-life":"In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged","unii":"0GXP746VXB","InChIKey":"SRZNHPXWXCNNDU-IXOPCIAXSA-N","route-of-elimination":"No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. In normal patients, from 51% to 81% of an administered dose of Cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations.","xml":"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","name":"Cefotetan","clearance":"* 1.8 +/- 0.1 L/h [elderly patients with normal renal function (.65 years)]\r\n* 1.8 +/- 0.3 L/h [healthy volunteers (aged 25 to 28 years)]","metabolism":"No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug.","id":"DB01330","indication":"For prophylaxis and treatment of bacterial infections.","drugbank-id":"DB01330"}]}